Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

- PMLiVE

Combined immunotherapies – potential and pitfalls

‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’

- PMLiVE

Lilly partners with AC Immune on tau drug for Alzheimer’s

Potential payments of $1.7bn to Swiss firm

- PMLiVE

Blue Latitude Health joins Fishawack Group of Companies

Blue Latitude Health announces a new partnership with Fishawack Group of Companies, fuelling our global growth.

Blue Latitude Health

- PMLiVE

Clark Health Communications to bring AI to the forefront with new deal

Partners up with Egg Digital

- PMLiVE

Merck exec steps down, two takes his place

Head of global human health Adam Schechter will transition to CEO advisor

- PMLiVE

FDA takes aim at pharma’s biosimilar-delaying tactics

Ever-rising cost of insulins also to be targeted

- PMLiVE

Circassia seeks shift to AIM after failing LSE criteria

Move comes after the drug developer suffered a string of immunotherapy defeats

- PMLiVE

Beneluxa: the future of European market access?

Andrew McConaghie talks to Beneluxa’s Marcel van Raaij and Biogen’s Erik Smet about their groundbreaking deal on Spinraza and what it means for European market access

- PMLiVE

Fishawack acquires Blue Latitude Health

Consultancy latest in string of strategic acquisitions for Fishawack

- PMLiVE

Axovant drops last ‘legacy’ drug to focus on gene therapies

Decision comes after nelotanserin failed to meet efficacy target

- PMLiVE

FDA clears Sandoz and Pear’s Opioid Use Disorder app

The app incorporates CBT to improve high relapse rates

- PMLiVE

As May delays, industry warns again of ‘no-deal’ Brexit

Brussels offers warm words, but no renegotiation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links